Fox Run Management L.L.C. Purchases Shares of 46,053 Bausch + Lomb Corporation $BLCO

Fox Run Management L.L.C. purchased a new stake in Bausch + Lomb Corporation (NYSE:BLCO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 46,053 shares of the company’s stock, valued at approximately $787,000.

A number of other large investors have also recently bought and sold shares of BLCO. Goldman Sachs Group Inc. grew its position in Bausch + Lomb by 428.7% in the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after acquiring an additional 242,993 shares during the period. Woodline Partners LP grew its position in Bausch + Lomb by 0.5% in the first quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after acquiring an additional 1,436 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Bausch + Lomb during the second quarter worth $200,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Bausch + Lomb during the second quarter worth $313,000. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Trading Down 2.7%

Shares of BLCO opened at $15.23 on Thursday. The company has a quick ratio of 0.99, a current ratio of 1.53 and a debt-to-equity ratio of 0.78. Bausch + Lomb Corporation has a 12-month low of $11.44 and a 12-month high of $18.92. The firm has a market capitalization of $5.44 billion, a PE ratio of -24.57, a price-to-earnings-growth ratio of 0.48 and a beta of 0.58. The stock’s fifty day simple moving average is $16.01 and its 200-day simple moving average is $16.60.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, research analysts predict that Bausch + Lomb Corporation will post 0.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

BLCO has been the topic of several research analyst reports. Citigroup set a $19.00 target price on Bausch + Lomb and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Bausch + Lomb in a report on Thursday, April 30th. Barclays increased their target price on Bausch + Lomb from $17.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. HC Wainwright increased their target price on Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, Stifel Nicolaus set a $16.00 target price on Bausch + Lomb in a report on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bausch + Lomb has a consensus rating of “Hold” and a consensus price target of $17.92.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.